Chugai Pharmabody Research Pte. Ltd. ('CPR') was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd (Chugai), a member of Roche group, in January 2012 and started operations on July 2, 2012. Located at Biopolis in
Singapore
, it aims to generate new antibody drugs based on Chugai's proprietary antibody engineering technologies, such as recycling antibody®, sweeping antibody®, bispecific antibody, various Fc engineered antibodies, and other new antibody engineering technologies that are under development. Position - Research Scientist in
Pharmacology Unit CPR is seeking a Research Scientist with strong expertise in both in vitro and in vivo experimental systems. The candidate will be responsible for designing and executing pharmacology studies, with a focus on disease target validation and characterization of pharmacological responses. A solid understanding of immunology, inflammation, and chronic disease pathogenesis is essential for succes...